IBRX Stock Analysis: Immunitybio | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.170m USD | 12M Return: 222.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 96.6M
Qual. Beats: 0
Rev. Trend: 95.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ImmunityBio, Inc. (NASDAQ: IBRX) is a San Diego-based biotechnology company developing next-generation immunotherapies that aim to activate the patients immune system to treat cancer and infectious diseases. The companys pipeline is built on multiple technology platforms, including cytokine fusion proteins, DNA and vaccine vectors, and cell therapies, which have produced first-in-human agents slated for trials in both liquid and solid tumors.
Its lead commercial product, Anktiva, is an FDA-approved immunotherapy used in combination with bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. A second key candidate, 3M-052, is a synthetic TLR7/8 agonist being advanced in multiple formulations. The company is headquartered in San Diego, California, and supports its work through collaboration agreements with the National Cancer Institute, Serum Institute of India, and BeOne Medicines, as well as license agreements with 3M Innovative Properties Company and the Access to Advanced Health Institute.
As a clinical-stage and early-commercial biotechnology firm, ImmunityBios business model centers on lengthy, capital-intensive R&D, with revenue dependent on the successful development, regulatory approval, and commercialization of a small number of biologic products. The FDA approval of Anktiva represents a significant milestone, as commercial-stage biotechnology companies typically transition from relying primarily on collaboration and licensing income to generating product sales revenue.
- Anktiva commercial launch drives bladder cancer revenue ramp
- Pipeline expansion targets additional cancer indications and label broadening
- Cash burn and equity raises pressure share count amid ongoing losses
| Net Income: -854.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.25 > 0.02 and ΔFCF/TA -5.31 > 1.0 |
| NWC/Revenue: 273.1% < 20% (prev 192.0%; Δ 81.06% < -1%) |
| CFO/TA -0.46 > 3% & CFO -294.4m > Net Income -854.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.03b) vs 12m ago 20.36% < -2% |
| Gross Margin: 93.79% > 18% (prev 71.96%; Δ 21.83% > 0.5%) |
| Asset Turnover: 29.67% > 50% (prev 10.28%; Δ 19.39% > 0%) |
| Interest Coverage Ratio: -6.62 > 6 (EBIT TTM -742.4m / Interest Expense TTM 112.1m) |
| A: 0.60 (Total Current Assets 453.0m - Total Current Liabilities 68.0m) / Total Assets 646.6m |
| B: -6.74 (Retained Earnings -4.36b / Total Assets 646.6m) |
| C: -1.56 (EBIT TTM -742.4m / Avg Total Assets 475.2m) |
| D: -0.57 (Book Value of Equity -870.0m / Total Liabilities 1.52b) |
| Altman-Z'' = -29.17 = D |
| DSRI: 0.55 (Receivables 43.3m/17.5m, Revenue 141.0m/31.2m) |
| GMI: 0.77 (GM 71.96% / 93.79%) |
| AQI: 0.81 (AQ_t 0.07 / AQ_t-1 0.09) |
| SGI: 4.52 (Revenue 141.0m / 31.2m) |
| TATA: -0.87 (NI -854.5m - CFO -294.4m) / TA 646.6m) |
| Beneish M = -1.29 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 8.76 with a total of 11,059,883 shares traded. Over the past week, the price has changed by -0.11%, over one month by +22.18%, over three months by +27.70% and over the past year by +222.06%.
Current recommended Stop Loss: 8.00 (which is 8.7% or 1.3 ATR below the current price).
Immunitybio has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy IBRX.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13 | 48.4% |
P/S = 65.0431
Revenue TTM = 141.0m USD
EBIT TTM = -742.4m USD
EBITDA TTM = -726.3m USD
Long Term Debt = 678.4m USD (from longTermDebt, last quarter)
Short Term Debt = 8.56m USD (from shortTermDebt, last quarter)
Debt = 1.17b USD (from shortLongTermDebtTotal, last quarter) + Leases 40.8m
Net Debt = 910.8m USD (calculated: Debt 1.17b - CCE 254.6m)
Enterprise Value = 10.1b USD (9.17b + Debt 1.17b - CCE 254.6m)
Interest Coverage Ratio = -6.62 (Ebit TTM -742.4m / Interest Expense TTM 112.1m)
EV/FCF = -12.48x (Enterprise Value 10.1b / FCF TTM -808.0m)
FCF Yield = -8.02% (FCF TTM -808.0m / Enterprise Value 10.1b)
FCF Margin = -573.1% (FCF TTM -808.0m / Revenue TTM 141.0m)
Net Margin = -606.2% (Net Income TTM -854.5m / Revenue TTM 141.0m)
Gross Margin = 93.79% ((Revenue TTM 141.0m - Cost of Revenue TTM 8.75m) / Revenue TTM)
Gross Margin QoQ = none% (prev 88.91%)
Tobins Q-Ratio = 15.59 (Enterprise Value 10.1b / Total Assets 646.6m)
Interest Expense / Debt = 9.62% (Interest Expense 112.1m / Debt 1.17b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -586.5m (EBIT -742.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.72 (Total Current Assets 453.0m / Total Current Liabilities 79.1m)
Debt / Equity = -1.34 (negative equity) (Debt 1.17b / totalStockholderEquity, last quarter -870.0m)
Debt / EBITDA = -1.25 (negative EBITDA) (Net Debt 910.8m / EBITDA -726.3m)
Debt / FCF = -1.13 (negative FCF - burning cash) (Net Debt 910.8m / FCF TTM -808.0m)
Total Stockholder Equity = -616.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -179.8% (out of range, set to none)
RoE = 138.7% (negative equity) (Net Income TTM -854.5m / Total Stockholder Equity -616.2m)
RoCE = -1.19k% (out of range, set to none) (EBIT -742.4m / Capital Employed (Equity -616.2m + L.T.Debt 678.4m))
RoIC = -101.1% (out of range, set to none) (NOPAT -586.5m / Invested Capital 580.2m)
WACC = 12.37% (E(9.17b)/V(10.3b) * Re(12.98%) + D(1.17b)/V(10.3b) * Rd(9.62%) * (1-Tc(0.21)))
Discount Rate = 12.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 27.86%
[DCF] Fair Price = unknown (Cash Flow -808.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.24 | # QB: 0
Revenue Correlation: 95.58 | Revenue CAGR: 1.12k% | SUE: 0.09 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.08 | Chg30d=-26.38% | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.07 | Chg30d=-16.67% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.85 | Chg30d=-220.75% | Revisions=-25% | GrowthEPS=-123.7% | GrowthRev=+96.3%
EPS next Year (2027-12-31): EPS=0.06 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+113.3% | GrowthRev=+103.3%
[Analyst] Revisions Ratio: -22% (up=2, down=4)